ALLERGAN RECEIVES FDA APPROVAL FOR ACUVAIL

The FDA has approved Allergan Inc.'s Acuvail (ketorolac tromethamine ophthalmic solution) 0.45%, an advanced, preservative-free formulation of the NSAID ketorolac indicated for the treatment of pain and inflammation following cataract surgery. According to the company, Acuvail is formulated at pH 6.8, enabling deionized drug delivery on the corneal surface, and contains carboxymethylcellulose, which enables the drug to adhere to the ocular surface and enhances patient comfort. The company expects Acuvail to be available to physicians and patients in the United States in September 2009.

Posted in: Allergan, Cataract surgery, Drug delivery, Non-steroidal anti-inflammatory drug, U.S. Food and Drug Administration